Drugs / GERSIZANGITIDE
GERSIZANGITIDE
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05859776 | Dec 2023 → Mar 2025 | wet macular degeneration | AsclepiX Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04746963 | Feb 2021 → Oct 2022 | wet macular degeneration | AsclepiX Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT04697758 | Dec 2020 → Oct 2022 | diabetic macular edema | AsclepiX Therapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GERSIZANGITIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095123 ↗ |
| Known as | AXT107 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04697758 ↗ |
| Known as | Gersizangitida | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095123 ↗ |
| Known as | Gersizangtide | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095123 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL5095123 ↗ |
| Route | Intravitreal | “Single intravitreal injection of AXT107 0.1 mg/eye” NCT04697758 ↗ |